Last updated: September 8, 2026
Abacavir sulfate/lamivudine/zidovudine, marketed as Trizivir, is a legacy fixed-dose HIV-1 treatment with limited commercial relevance. Its principal market value has eroded because the regimen requires twice-daily dosing, contains zidovudine, carries cumulative toxicity concerns, and has been displaced by once-daily integrase inhibitor combinations. Core compound and combination patent protection has expired or is no longer commercially material. Current revenue is not separately disclosed by ViiV Healthcare or GSK, but the product is expected to contribute negligible revenue relative to newer HIV products such as Dovato, Triumeq, Rukobia, and long-acting Cabenuva.
| Category |
Assessment |
| Active ingredients |
Abacavir sulfate, lamivudine, zidovudine |
| Brand |
Trizivir |
| Original sponsor |
GlaxoSmithKline |
| Current commercial group |
ViiV Healthcare, majority owned by GSK |
| FDA approval |
October 2000 |
| Dosage |
One tablet twice daily |
| Regulatory role |
Legacy treatment; not a preferred initial HIV regimen |
| Patent position |
Core product and combination protection expired |
| Generic risk |
High, although commercial generic availability is limited by low demand |
| Revenue trajectory |
Long-term decline; standalone sales not publicly reported |
| Strategic value |
Minimal product revenue; residual value in treatment access and portfolio continuity |
What is Trizivir and how does the HIV combination work?
Trizivir combines three nucleoside reverse transcriptase inhibitors, or NRTIs:
- Abacavir sulfate
- Lamivudine
- Zidovudine
The product blocks HIV reverse transcriptase after intracellular conversion of the active ingredients to their triphosphate forms. The three-drug combination was designed to provide a complete antiretroviral regimen in a single tablet.
The FDA approved Trizivir on October 3, 2000, under NDA 020564. The approved dosing regimen is one tablet twice daily, with or without food. The product is intended for adults and adolescents weighing at least 40 kilograms, subject to labeling limitations and clinical judgment.[1]
The regimen is pharmacologically effective when HIV is susceptible to all three components. Its commercial position weakened as clinical practice shifted toward once-daily regimens based on integrase strand transfer inhibitors, including dolutegravir and bictegravir.
When does Trizivir lose exclusivity?
Trizivir has no meaningful remaining market exclusivity in the United States.
The underlying NRTI patents expired at different times. Zidovudine patents are substantially older, and lamivudine and abacavir compound patents also expired before the current period. The fixed-dose combination was covered by later formulation and combination patents, including patents associated with the abacavir, lamivudine, and zidovudine combination. Those protections reached the end of their normal patent terms during the 2010s.
| Protection category |
Commercial status |
| Zidovudine composition patents |
Expired |
| Lamivudine composition patents |
Expired |
| Abacavir composition patents |
Expired |
| Trizivir combination patents |
Expired or commercially exhausted |
| Pediatric exclusivity |
Historical only |
| Current U.S. exclusivity |
None of economic significance |
| Current patent-based launch barrier |
Low |
The original abacavir patent estate was more important for Ziagen and Kivexa/Epzicom than for Trizivir. Trizivir’s commercial protection depended on the combination product, but the product did not retain a durable lifecycle advantage after the arrival of more convenient and better-tolerated regimens.
What is the Orange Book status of Trizivir?
The FDA’s Orange Book historically listed Trizivir under the original GSK NDA. Any historical patents associated with the product are expired, and the product does not have a current exclusivity position capable of supporting a premium branded market.
Orange Book status does not by itself establish that a generic equivalent is commercially available. A manufacturer may avoid filing an ANDA when the market is small, the reference product has declining utilization, or the manufacturing economics are unattractive. The absence of a visible generic equivalent would therefore not restore meaningful pricing power to the brand.
The most important commercial distinction is between legal freedom to enter and economically rational entry. Trizivir is legally exposed to generic substitution but may be commercially unattractive because current HIV treatment demand has moved to newer products.
What formulation patents protect abacavir, lamivudine, and zidovudine?
The formulation and combination estate historically protected the use of the three active ingredients in a single oral tablet. The principal technical value was convenience and regimen simplification rather than a novel molecular mechanism.
Potential patent categories included:
- Fixed-dose tablet compositions.
- Ratios and dosage strengths of abacavir, lamivudine, and zidovudine.
- Manufacturing methods for combining chemically distinct NRTIs.
- Pharmaceutical excipient systems and tablet stability.
- Method-of-treatment claims for HIV infection.
These categories no longer provide a material barrier to competition. The active ingredients are small molecules with established synthesis routes, and the tablet does not require a complex delivery device, sterile manufacturing process, biologic cell line, or specialized cold chain.
How strong is the Trizivir patent estate?
The current patent estate is weak from a commercial defense perspective.
Patent-strength assessment
| Factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Combination protection |
Expired or near-zero residual value |
| Formulation complexity |
Low |
| Manufacturing difficulty |
Low to moderate |
| Regulatory exclusivity |
None of consequence |
| Patent litigation leverage |
Low |
| Ability to delay generic launch |
Minimal |
| Lifecycle-management potential |
Low |
The product does not have the characteristics of a protected specialty pharmaceutical. It is a conventional oral tablet composed of off-patent small molecules. A new patent would generally need to claim a genuinely differentiated formulation, dosing method, or patient population. Such claims would face substantial validity and obviousness risks given the maturity of the ingredients and the long history of clinical use.
Which companies are challenging Trizivir?
There is no major current Paragraph IV challenge shaping the Trizivir market.
Historical generic activity around the individual ingredients has been more important than litigation over the full three-drug combination. Abacavir, lamivudine, and zidovudine are available in multiple generic forms as separate products, and lamivudine/zidovudine combinations have long been genericized in several markets.
The practical competitive threat is not a single branded challenger. It is substitution by:
- Generic individual NRTIs.
- Generic lamivudine/zidovudine products.
- Tenofovir-based combinations.
- Dolutegravir-based regimens.
- Bictegravir-based single-tablet regimens.
- Lower-cost public-sector HIV procurement programs.
No current high-value settlement agreement or major patent dispute appears to create a new exclusivity window for Trizivir.
What is the FDA regulatory status of Trizivir?
Trizivir remains a legacy FDA-approved HIV product, but its clinical role has narrowed significantly.
The FDA label includes major safety warnings associated with abacavir and zidovudine. Abacavir carries a risk of potentially fatal hypersensitivity reactions associated with HLA-B5701. Patients who test positive for HLA-B5701 should not receive abacavir. The label also warns about lactic acidosis, severe hepatomegaly with steatosis, immune reconstitution syndrome, and hematologic toxicity related particularly to zidovudine.[1]
The U.S. Department of Health and Human Services HIV treatment guidelines no longer position Trizivir as a preferred initial regimen. Modern treatment generally favors an integrase inhibitor combined with two NRTIs, with regimen selection based on resistance, renal and hepatic function, pregnancy status, comorbidities, and drug interactions.[2]
The clinical decline is structural. Trizivir has:
- Twice-daily dosing.
- Three NRTIs rather than an integrase-based regimen.
- Zidovudine-associated anemia and neutropenia concerns.
- Abacavir hypersensitivity screening requirements.
- Fewer advantages in treatment-naive patients than current standard regimens.
How does Trizivir compare with competing HIV drugs?
| Product |
Core regimen |
Dosing |
Current market position |
| Trizivir |
Abacavir/lamivudine/zidovudine |
Twice daily |
Legacy, limited use |
| Triumeq |
Dolutegravir/abacavir/lamivudine |
Once daily |
Established but declining after generic exposure and label constraints |
| Dovato |
Dolutegravir/lamivudine |
Once daily |
Important two-drug regimen |
| Biktarvy |
Bictegravir/emtricitabine/tenofovir alafenamide |
Once daily |
Major first-line and switch product |
| Atripla, historical |
Efavirenz/tenofovir/emtricitabine |
Once daily |
Largely displaced |
| Generic TLD |
Tenofovir/lamivudine/dolutegravir |
Once daily |
Major low-cost global regimen |
Biktarvy and Dovato offer simpler dosing and stronger contemporary guideline positioning. Triumeq retains clinical relevance for selected patients but competes with Dovato and other dolutegravir products. Trizivir lacks a comparable commercial differentiator.
What generic entry risks exist for Trizivir?
Generic entry risk is high in legal terms and moderate in practical terms.
A generic manufacturer could rely on established active ingredients and a conventional oral-tablet platform. The principal barriers would be:
- Bioequivalence development.
- Stability and impurity control.
- Demonstration of the required fixed-dose composition.
- Commercial scale and distribution.
- Limited demand from prescribers and treatment programs.
The product’s low market value can deter entry. A generic company may prefer to supply the individual components or a two-drug combination rather than incur the cost of maintaining a dedicated three-drug product with limited volume.
Generic substitution is also constrained by clinical practice. Even if a low-cost equivalent is available, physicians may favor modern regimens because they reduce pill burden and avoid zidovudine-related toxicity.
What is the financial trajectory of Trizivir?
Trizivir’s standalone revenue is not publicly broken out in GSK or ViiV financial reporting. The companies report HIV revenue at the brand or portfolio level, while older products may be grouped into “other” or included within a broader HIV franchise. A precise annual revenue series for Trizivir cannot be derived from public company filings.
The financial trajectory can still be assessed from market structure:
| Period |
Financial trajectory |
| 2000-2005 |
Commercial growth after FDA approval; value from triple-NRTI convenience |
| 2006-2010 |
Increasing competition from newer fixed-dose and once-daily regimens |
| 2011-2017 |
Patent erosion and declining clinical preference |
| 2018-2022 |
Residual sales concentrated in legacy patients and selected markets |
| 2023 onward |
Low-volume mature product with limited strategic investment |
The product’s revenue decline reflects demand migration rather than a single patent cliff. The shift to integrase inhibitor therapy reduced both new-patient starts and maintenance use. HIV treatment markets grew in patient count, but Trizivir did not participate proportionately in that growth.
For ViiV, the economically relevant products are newer or longer-duration therapies. GSK’s annual reports identify ViiV as a major business, but they do not identify Trizivir as a material standalone revenue contributor.[3] Trizivir therefore has negligible impact on consolidated GSK revenue, operating profit, or valuation.
Does Trizivir have meaningful licensing or partnership value?
Trizivir is associated with GSK’s historical HIV research and commercial franchise. ViiV Healthcare was established in 2009 as a joint venture between GSK and Pfizer to focus on HIV medicines; Shionogi later became a shareholder.[4]
The ViiV structure has strategic relevance for dolutegravir, cabotegravir, long-acting therapy, and newer HIV assets. It does not create a material licensing premium for Trizivir. The product has no visible platform value comparable to cabotegravir, no meaningful formulation moat, and no major partnership-driven expansion opportunity.
Any remaining commercial value is operational:
- Maintaining supply for established patients.
- Supporting treatment access in selected countries.
- Retaining a complete historical HIV portfolio.
- Generating residual cash flow from existing registrations.
What patent litigation affects Trizivir?
No current high-value litigation appears to materially affect Trizivir’s commercial outlook. The product’s patent disputes, if any, are no longer central to the HIV competitive landscape.
The litigation profile differs from that of newer HIV products. Trizivir does not face a major pending biosimilar dispute because it is a small-molecule product, not a biologic. It also lacks a significant formulation or delivery-system patent dispute that could materially delay competition.
The greater risk is regulatory and commercial substitution. Prescribers, payers, and treatment programs can move patients to newer regimens without waiting for a patent ruling.
What manufacturing and geographic barriers remain?
Manufacturing barriers are limited. The product uses established small-molecule active ingredients and conventional oral-tablet technology. Production does not require biologic fermentation, aseptic fill-finish, complex device assembly, or controlled-temperature distribution.
Geographic demand differs by market:
- United States: limited legacy use, high pressure from modern branded and generic regimens.
- Western Europe: limited use because treatment guidelines favor integrase inhibitor combinations.
- Low- and middle-income countries: potential residual use where procurement systems prioritize low-cost NRTI combinations, but tenofovir/lamivudine/dolutegravir has become the dominant low-cost benchmark.
- Markets with older formularies: higher probability of continued use, but volumes remain constrained.
WHO guidance and public-sector procurement trends favor dolutegravir-based regimens over older zidovudine-containing combinations.[5]
What is the outlook for generic launch and revenue exposure?
A generic launch would have low pricing power and limited market expansion potential. The most probable commercial scenarios are:
| Scenario |
Probability assessment |
Market effect |
| No major dedicated generic launch |
High |
Continued low-volume branded or legacy supply |
| Small-market generic launch |
Moderate |
Price erosion with limited unit growth |
| Broad global generic uptake |
Low |
Unlikely because newer low-cost regimens dominate |
| Product withdrawal or further market contraction |
Moderate to high |
Patients migrate to preferred alternatives |
| Regulatory or patent-driven exclusivity renewal |
Very low |
No apparent basis |
Trizivir’s revenue exposure for GSK/ViiV is immaterial compared with the company’s current HIV portfolio. Its decline does not create a material earnings event. The principal financial issue is portfolio maintenance, not revenue preservation.
Key Takeaways
- Trizivir is the fixed-dose combination of abacavir sulfate, lamivudine, and zidovudine.
- FDA approval occurred in October 2000 under NDA 020564.
- Core compound and combination patent protection has expired.
- No meaningful current Orange Book exclusivity remains.
- The product is not a preferred initial HIV regimen under contemporary treatment guidelines.
- Biktarvy, Dovato, Triumeq, and generic dolutegravir-based combinations have displaced Trizivir in most treatment settings.
- Public filings do not disclose standalone Trizivir revenue.
- The product’s financial trajectory is long-term decline with residual legacy demand.
- Generic entry is legally feasible but may be commercially unattractive because of low demand.
- Biosimilar risk is not relevant because Trizivir is a small-molecule tablet.
- Trizivir has minimal impact on ViiV’s valuation, earnings, or strategic HIV positioning.
FAQs About Abacavir, Lamivudine, and Zidovudine
Is Trizivir still prescribed?
Yes, but use is limited. It may remain available for selected patients or in markets with legacy treatment protocols, but it is not a preferred first-line regimen in current U.S. HIV guidelines.
Is there a generic version of Trizivir?
The individual ingredients and related two-drug combinations are generic in many markets. Availability of a dedicated generic abacavir/lamivudine/zidovudine tablet is more limited and varies by country.
Does Trizivir have active U.S. patents?
No commercially meaningful exclusivity is expected to remain. The relevant compound and combination patents reached the end of their patent terms.
Why did Trizivir decline despite growth in the HIV treatment market?
Patient growth benefited newer regimens. Trizivir lost share because of twice-daily dosing, zidovudine toxicity concerns, abacavir hypersensitivity screening, and the superior guideline position of integrase inhibitor combinations.
Is Trizivir revenue material to GSK?
No. GSK and ViiV do not publicly report a material standalone Trizivir revenue stream. The product is economically insignificant compared with ViiV’s current HIV portfolio.
References
- U.S. Food and Drug Administration. (2023). Trizivir (abacavir sulfate, lamivudine, and zidovudine) prescribing information.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
- GSK plc. (2024). Annual report 2023.
- ViiV Healthcare. (2024). About ViiV Healthcare and company history.
- World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach.
